Shilpa Medicare receives USFDA approval for Varenicline Tablets
Shilpa Medicare has received approval from USFDA for Varenicline Tablets, 0.5 and 1 mg.
The total US market for this product is around 203 M USD.
Shilpa's product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism).
Varenicline Tablets are indicated for smoking cessation; it helps people to quit smoking.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content